cGP
IGF-1 Bioavailability Regulator & Neuroprotective Peptide
DoseGear research brief
Endogenous cyclic dipeptide found in plasma, breast milk, and cerebrospinal fluid. Functions as metabolite of IGF-1, regulating its bioavailability through competitive binding to IGFBP-3. Demonstrates neuroprotective, cognitive-enhancing, and cardioprotective properties supported by clinical trials.
Competes with IGF-1 for IGFBP-3 binding, normalizing bioavailable IGF-1 levels. Acts as positive allosteric modulator of AMPA and GABA-A receptors. Increases BDNF levels via Akt/MDM2-p53 pathway activation.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Endogenous cyclic dipeptide associated with IGF-related metabolism.
IGF bioavailability, neuroprotection, and vascular research through proposed modulation of IGF-binding-protein interactions.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
No profile entries reported.
IGF-1 Homeostasis Regulation Study
Alzheimer's Mouse Model Study
Parkinson's Disease Clinical Study
Stroke Recovery & Cognitive Function Review
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
